![Catherine Madigan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: - $ am 30.09.2026
Catherine Madigan is Chief Medical Officer at Hemab Therapeutics Holdings, Inc. since 2025.
Former positions include Senior Medical Director at Alnylam Pharmaceuticals, Inc., Vice President & Head-Clinical Development at Syros Pharmaceuticals, Inc., and Chief Medical Officer at Syndax Pharmaceuticals, Inc. from 2022 to 2024.
Education includes an undergraduate degree from Dartmouth College and a doctorate from Keck School of Medicine of USC.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.05.2026 | 0 ( -.--% ) | - $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| HEMAB THERAPEUTICS HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 20.12.2024 |
| ALNYLAM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| SYROS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Dartmouth College
 Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Syros Pharmaceuticals, Inc.
 Syros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which developing care for the frontline treatment of patients with hematologic malignancies | Health Technology |
Keck School of Medicine of USC
 Keck School of Medicine of USC Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HEMAB THERAPEUTICS INC.
 HEMAB THERAPEUTICS INC. BiotechnologyHealth Technology Engages in research and development of prophylactic therapeutics for bleeding disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
